Detalhe da pesquisa
1.
What makes a space safe? Consumers' perspectives on a mental health safe space.
Int J Ment Health Nurs
; 32(5): 1355-1364, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37231985
2.
Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinases.
Bioorg Med Chem Lett
; 20(14): 4045-9, 2010 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20561787
3.
Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2.
Bioorg Med Chem
; 18(2): 707-18, 2010 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20022510
4.
2-Arylamino-6-ethynylpurines are cysteine-targeting irreversible inhibitors of Nek2 kinase.
RSC Med Chem
; 11(6): 707-731, 2020 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33479670
5.
Research ethics and the use of visual images in research with people with intellectual disability.
J Intellect Dev Disabil
; 34(1): 45-54, 2009 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19234978
6.
In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors.
Cancer Res
; 67(5): 2206-16, 2007 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17332351
7.
4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.
J Med Chem
; 51(2): 196-218, 2008 Jan 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-18020435
8.
Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues.
Mol Cancer Ther
; 6(4): 1198-211, 2007 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-17431102
9.
Inhibition of Hsp90 with synthetic macrolactones: synthesis and structural and biological evaluation of ring and conformational analogs of radicicol.
Chem Biol
; 13(11): 1203-15, 2006 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17114002
10.
Structure-guided design of purine-based probes for selective Nek2 inhibition.
Oncotarget
; 8(12): 19089-19124, 2017 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-27833088
11.
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
Oncotarget
; 7(3): 2329-42, 2016 Jan 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-26295308
12.
Solid-phase immunoassays in mechanism-based drug discovery: their application in the development of inhibitors of the molecular chaperone heat-shock protein 90.
Assay Drug Dev Technol
; 3(3): 273-85, 2005 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-15971989
13.
Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms.
Chem Biol
; 11(6): 775-85, 2004 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-15217611
14.
Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.
Cancer Res
; 75(16): 3340-54, 2015 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26202014
15.
Correction: In vitro Biological Characterization of a Novel, Synthetic Diaryl Pyrazole Resorcinol Class of Heat Shock Protein 90 Inhibitors.
Cancer Res
; 79(1): 287, 2019 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30602624
16.
The discovery of potent ribosomal S6 kinase inhibitors by high-throughput screening and structure-guided drug design.
Oncotarget
; 4(10): 1647-61, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24072592
17.
Fragment-based screening maps inhibitor interactions in the ATP-binding site of checkpoint kinase 2.
PLoS One
; 8(6): e65689, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23776527
18.
Structure-based design of orally bioavailable 1H-pyrrolo[3,2-c]pyridine inhibitors of mitotic kinase monopolar spindle 1 (MPS1).
J Med Chem
; 56(24): 10045-65, 2013 Dec 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-24256217
19.
Design of potent and selective hybrid inhibitors of the mitotic kinase Nek2: structure-activity relationship, structural biology, and cellular activity.
J Med Chem
; 55(7): 3228-41, 2012 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-22404346
20.
CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs.
Clin Cancer Res
; 18(20): 5650-61, 2012 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22929806